Search Results

You are looking at 81 - 90 of 165 items for :

  • "early breast cancer" x
  • All content x
Clear All
Full access

Titilayo O. Adegboyega, Jeffrey Landercasper, Jared H. Linebarger, Jeanne M. Johnson, Jeremiah J. Andersen, Leah L. Dietrich, Collin D. Driscoll, Meghana Raghavendra, Anusha R. Madadi, Mohammed Al-Hamadani, Choua A. Vang, Kristen A. Marcou, Jane Hudak, and Ronald S. Go

– 160 . 12. Cooper KL Meng Y Harnan S . Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation . Health

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

recurrence for early breast cancer exceeds 10% at 5 years, avoidance of 4 local recurrences at 5 years predicts one life saved at 15 years. 23 Assuming that these findings have no relevance to DCIS, locoregional management would be cavalier. Conclusions

Full access

Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom

services in early-stage breast cancer (ESBC), stating, “Don't perform PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis.” 1 For these recommendations, the Choosing Wisely initiative defines early

Full access

Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff

cancer . J Clin Oncol 2001 ; 19 : 980 - 991 . 7 Olivotto IA Bajdik CD Ravdin PM . Population-based validation of the prognostic model ADJUVANT! for early breast cancer . J Clin Oncol 2005 ; 23 : 2716 - 2725 . 8 Love N

Full access

Melinda L. Telli and Ronald M. Witteles

cyclophosphamide followed by docetaxel and trastuzumab (AC->TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract] . Presented at the 29th Annual San Antonio Breast Cancer Symposium ; December 14

Full access

Aki Morikawa and Andrew D. Seidman

-refractory prostate cancer . Clin Genitourin Cancer 2006 ; 5 : 131 – 137 . 25. Martin M Rodriguez-Lescure A Ruiz A . Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer . Breast Cancer Res Treat 2010 ; 123 : 149

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

effective for minimizing loss of BMD in women receiving ovarian suppression with GnRH. 137 , 154 In the ABCSG-12 trial, the effect of adding zoledronic acid was examined in premenopausal patients with early breast cancer treated with ovarian suppression

Full access

Adrienne G. Waks and Ann H. Partridge

.9%, respectively, in the PROMISE trial (Prevention of Menopause Induced by Chemotherapy: A Study in Early Breast Cancer Patients) ( P <.001). 20 Additionally, in POEMS, significantly more pregnancies were seen in women who received goserelin (21%) than in those

Full access

Rita A. Mukhtar, Jasmine M. Wong, and Laura J. Esserman

chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet 2005 ; 365 : 1687 – 1717 . 11. Pace LE Keating NL . A systematic assessment of benefits and risks to guide

Full access

Noam VanderWalde, Reshma Jagsi, Efrat Dotan, Joel Baumgartner, Ilene S. Browner, Peggy Burhenn, Harvey Jay Cohen, Barish H. Edil, Beatrice Edwards, Martine Extermann, Apar Kishor P. Ganti, Cary Gross, Joleen Hubbard, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O'Connor, Hope S. Rugo, Randall W. Rupper, Dale Shepard, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Tanya Wildes, Mary Anne Bergman, Hema Sundar, and Arti Hurria

early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977 . 16. Hughes KS Schnaper LA Bellon JR . Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB